The nephrologist's anticoagulation treatment patterns/regimens in chronic hemodialysis patients with atrial fibrillation

Simonetta Genovesi, Emanuela Rossi, Daniela Pogliani, Maurizio Gallieni, Andrea Stella, Fabio Badiali, Ferruccio Conte, Sonia Pasquali, Silvio Bertoli, Patrizia Ondei, Giuseppe Bonforte, Claudio Pozzi, Maria Grazia Valsecchi, Antonio Santoro

Research output: Contribution to journalArticle

Abstract

Background: The prevalence of atrial fibrillation (AF) is high in hemodialysis (HD) patients. It was suggested that oral anticoagulant therapy (OAT), the choice treatment for reducing the thromboembolic risk in AF patients, increases the incidence of both ischemic and hemorrhagic strokes in the HD population. Moreover, the therapy-related bleeding risk is particularly high in these patients. For these reasons there is no agreement on the use of OAT in HD patients with AF. The aim of this study was to evaluate the criteria adopted by nephrologists in prescribing OAT in HD patients with AF. Methods: All the patients presenting AF (paroxysmal, persistent or permanent) at 31/10/2010 (n = 290) were recruited from 1529 HD patients from ten Italian HD centres. To detect factors related to OAT administration the main clinical features, CHADS2 and HASBLED scores were evaluated in logistic regression models. Results: The presence of permanent AF (OR = 4.28, p <0.0001) was the only clinical factor directly associated to OAT administration, while previous bleedings (OR = 0.35, p = 0.004) were inversely related. The CHADS2 score was not associated with OAT prescription (OR = 0.85, p = 0.08), while an inverse relation was found with the hemorrhagic risk score (OR = 0.74, p = 0.03). Conclusion: A high AF prevalence was observed in our HD population, but less than 50 % of these patients received OAT. Patients with permanent AF were more frequently treated with warfarin, while OAT administration was uncommon in those with previous bleedings. The thromboembolic risk score was not associated with warfarin prescription, while there was an inverse relation with the hemorrhagic risk score.

Original languageEnglish
Pages (from-to)187-192
Number of pages6
JournalJournal of Nephrology
Volume27
Issue number2
DOIs
Publication statusPublished - 2014

Fingerprint

Atrial Fibrillation
Renal Dialysis
Anticoagulants
Therapeutics
Warfarin
Hemorrhage
Prescriptions
Logistic Models
Nephrologists
Population
Stroke
Incidence

Keywords

  • Atrial fibrillation
  • Bleeding
  • Hemodialysis
  • Oral anticoagulant therapy
  • Stroke

ASJC Scopus subject areas

  • Nephrology
  • Medicine(all)

Cite this

Genovesi, S., Rossi, E., Pogliani, D., Gallieni, M., Stella, A., Badiali, F., ... Santoro, A. (2014). The nephrologist's anticoagulation treatment patterns/regimens in chronic hemodialysis patients with atrial fibrillation. Journal of Nephrology, 27(2), 187-192. https://doi.org/10.1007/s40620-013-0030-3

The nephrologist's anticoagulation treatment patterns/regimens in chronic hemodialysis patients with atrial fibrillation. / Genovesi, Simonetta; Rossi, Emanuela; Pogliani, Daniela; Gallieni, Maurizio; Stella, Andrea; Badiali, Fabio; Conte, Ferruccio; Pasquali, Sonia; Bertoli, Silvio; Ondei, Patrizia; Bonforte, Giuseppe; Pozzi, Claudio; Valsecchi, Maria Grazia; Santoro, Antonio.

In: Journal of Nephrology, Vol. 27, No. 2, 2014, p. 187-192.

Research output: Contribution to journalArticle

Genovesi, S, Rossi, E, Pogliani, D, Gallieni, M, Stella, A, Badiali, F, Conte, F, Pasquali, S, Bertoli, S, Ondei, P, Bonforte, G, Pozzi, C, Valsecchi, MG & Santoro, A 2014, 'The nephrologist's anticoagulation treatment patterns/regimens in chronic hemodialysis patients with atrial fibrillation', Journal of Nephrology, vol. 27, no. 2, pp. 187-192. https://doi.org/10.1007/s40620-013-0030-3
Genovesi, Simonetta ; Rossi, Emanuela ; Pogliani, Daniela ; Gallieni, Maurizio ; Stella, Andrea ; Badiali, Fabio ; Conte, Ferruccio ; Pasquali, Sonia ; Bertoli, Silvio ; Ondei, Patrizia ; Bonforte, Giuseppe ; Pozzi, Claudio ; Valsecchi, Maria Grazia ; Santoro, Antonio. / The nephrologist's anticoagulation treatment patterns/regimens in chronic hemodialysis patients with atrial fibrillation. In: Journal of Nephrology. 2014 ; Vol. 27, No. 2. pp. 187-192.
@article{c173c988a2f24170890eaf93e0685b99,
title = "The nephrologist's anticoagulation treatment patterns/regimens in chronic hemodialysis patients with atrial fibrillation",
abstract = "Background: The prevalence of atrial fibrillation (AF) is high in hemodialysis (HD) patients. It was suggested that oral anticoagulant therapy (OAT), the choice treatment for reducing the thromboembolic risk in AF patients, increases the incidence of both ischemic and hemorrhagic strokes in the HD population. Moreover, the therapy-related bleeding risk is particularly high in these patients. For these reasons there is no agreement on the use of OAT in HD patients with AF. The aim of this study was to evaluate the criteria adopted by nephrologists in prescribing OAT in HD patients with AF. Methods: All the patients presenting AF (paroxysmal, persistent or permanent) at 31/10/2010 (n = 290) were recruited from 1529 HD patients from ten Italian HD centres. To detect factors related to OAT administration the main clinical features, CHADS2 and HASBLED scores were evaluated in logistic regression models. Results: The presence of permanent AF (OR = 4.28, p <0.0001) was the only clinical factor directly associated to OAT administration, while previous bleedings (OR = 0.35, p = 0.004) were inversely related. The CHADS2 score was not associated with OAT prescription (OR = 0.85, p = 0.08), while an inverse relation was found with the hemorrhagic risk score (OR = 0.74, p = 0.03). Conclusion: A high AF prevalence was observed in our HD population, but less than 50 {\%} of these patients received OAT. Patients with permanent AF were more frequently treated with warfarin, while OAT administration was uncommon in those with previous bleedings. The thromboembolic risk score was not associated with warfarin prescription, while there was an inverse relation with the hemorrhagic risk score.",
keywords = "Atrial fibrillation, Bleeding, Hemodialysis, Oral anticoagulant therapy, Stroke",
author = "Simonetta Genovesi and Emanuela Rossi and Daniela Pogliani and Maurizio Gallieni and Andrea Stella and Fabio Badiali and Ferruccio Conte and Sonia Pasquali and Silvio Bertoli and Patrizia Ondei and Giuseppe Bonforte and Claudio Pozzi and Valsecchi, {Maria Grazia} and Antonio Santoro",
year = "2014",
doi = "10.1007/s40620-013-0030-3",
language = "English",
volume = "27",
pages = "187--192",
journal = "Journal of Nephrology",
issn = "1121-8428",
publisher = "Springer International Publishing",
number = "2",

}

TY - JOUR

T1 - The nephrologist's anticoagulation treatment patterns/regimens in chronic hemodialysis patients with atrial fibrillation

AU - Genovesi, Simonetta

AU - Rossi, Emanuela

AU - Pogliani, Daniela

AU - Gallieni, Maurizio

AU - Stella, Andrea

AU - Badiali, Fabio

AU - Conte, Ferruccio

AU - Pasquali, Sonia

AU - Bertoli, Silvio

AU - Ondei, Patrizia

AU - Bonforte, Giuseppe

AU - Pozzi, Claudio

AU - Valsecchi, Maria Grazia

AU - Santoro, Antonio

PY - 2014

Y1 - 2014

N2 - Background: The prevalence of atrial fibrillation (AF) is high in hemodialysis (HD) patients. It was suggested that oral anticoagulant therapy (OAT), the choice treatment for reducing the thromboembolic risk in AF patients, increases the incidence of both ischemic and hemorrhagic strokes in the HD population. Moreover, the therapy-related bleeding risk is particularly high in these patients. For these reasons there is no agreement on the use of OAT in HD patients with AF. The aim of this study was to evaluate the criteria adopted by nephrologists in prescribing OAT in HD patients with AF. Methods: All the patients presenting AF (paroxysmal, persistent or permanent) at 31/10/2010 (n = 290) were recruited from 1529 HD patients from ten Italian HD centres. To detect factors related to OAT administration the main clinical features, CHADS2 and HASBLED scores were evaluated in logistic regression models. Results: The presence of permanent AF (OR = 4.28, p <0.0001) was the only clinical factor directly associated to OAT administration, while previous bleedings (OR = 0.35, p = 0.004) were inversely related. The CHADS2 score was not associated with OAT prescription (OR = 0.85, p = 0.08), while an inverse relation was found with the hemorrhagic risk score (OR = 0.74, p = 0.03). Conclusion: A high AF prevalence was observed in our HD population, but less than 50 % of these patients received OAT. Patients with permanent AF were more frequently treated with warfarin, while OAT administration was uncommon in those with previous bleedings. The thromboembolic risk score was not associated with warfarin prescription, while there was an inverse relation with the hemorrhagic risk score.

AB - Background: The prevalence of atrial fibrillation (AF) is high in hemodialysis (HD) patients. It was suggested that oral anticoagulant therapy (OAT), the choice treatment for reducing the thromboembolic risk in AF patients, increases the incidence of both ischemic and hemorrhagic strokes in the HD population. Moreover, the therapy-related bleeding risk is particularly high in these patients. For these reasons there is no agreement on the use of OAT in HD patients with AF. The aim of this study was to evaluate the criteria adopted by nephrologists in prescribing OAT in HD patients with AF. Methods: All the patients presenting AF (paroxysmal, persistent or permanent) at 31/10/2010 (n = 290) were recruited from 1529 HD patients from ten Italian HD centres. To detect factors related to OAT administration the main clinical features, CHADS2 and HASBLED scores were evaluated in logistic regression models. Results: The presence of permanent AF (OR = 4.28, p <0.0001) was the only clinical factor directly associated to OAT administration, while previous bleedings (OR = 0.35, p = 0.004) were inversely related. The CHADS2 score was not associated with OAT prescription (OR = 0.85, p = 0.08), while an inverse relation was found with the hemorrhagic risk score (OR = 0.74, p = 0.03). Conclusion: A high AF prevalence was observed in our HD population, but less than 50 % of these patients received OAT. Patients with permanent AF were more frequently treated with warfarin, while OAT administration was uncommon in those with previous bleedings. The thromboembolic risk score was not associated with warfarin prescription, while there was an inverse relation with the hemorrhagic risk score.

KW - Atrial fibrillation

KW - Bleeding

KW - Hemodialysis

KW - Oral anticoagulant therapy

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=84901022284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901022284&partnerID=8YFLogxK

U2 - 10.1007/s40620-013-0030-3

DO - 10.1007/s40620-013-0030-3

M3 - Article

C2 - 24430763

AN - SCOPUS:84901022284

VL - 27

SP - 187

EP - 192

JO - Journal of Nephrology

JF - Journal of Nephrology

SN - 1121-8428

IS - 2

ER -